Study title: A phase III, open, randomised, controlled multicentre study to evaluate the immunogenicity and safety of one dose of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella vaccine (MeMuRu- OKA) given to healthy children 4 to 6 years of age previously primed with one dose of measles-mumpsrubella vaccine (either Priorix™ or M-M-R II™) in their second year of life and presumed seronegative for varicella.
Type of medicine: Non-centrally authorised vaccines | |||||
Therapeutic area: Virus Diseases | |||||
Brands: Please see report, Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: Live attenuated measles, mumps, rubella, varicella vaccine | |||||
ATC code: | |||||
Document link: | |||||
Document date: 2011-11-22 | |||||
Study number: 208136/014 (MeMuRu-OKA-014) | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |